{"release":"wpf-research-journeys","version":"1.0.0","checkedOn":"2026-11-13","verificationLabel":"AI-assisted source verification","humanReview":"none recorded","slug":"elamipretide","result":{"resultId":"mmpower-3-6mwt-24w","trial":"MMPOWER-3 (phase 3, double-blind, placebo-controlled)","comparison":"Elamipretide 40 mg once daily vs placebo, subcutaneous","registryId":"NCT03323749","pmid":"37268435","doi":"10.1212/WNL.0000000000207402","population":"218 adults with genetically confirmed primary mitochondrial myopathy (109 elamipretide, 109 placebo)","comparator":"Placebo, subcutaneous once daily for 24 weeks","endpoint":"Co-primary: change from baseline in six-minute walk distance, and in the PMMSA total fatigue score","timePoint":"Week 24","result":"Primary endpoints not met. Difference in least-squares mean change, elamipretide minus placebo: six-minute walk distance -3.2 m (p=0.69); total fatigue score -0.07 (p=0.37).","uncertainty":"Six-minute walk distance difference: 95% CI -18.7 to 12.3 m. Total fatigue score difference: 95% CI -0.10 to 0.26 as printed in the abstract.","locator":"Neurology 2023 abstract (PubMed 37268435): participants, endpoints and both differences. ClinicalTrials.gov NCT03323749 results, primary outcome measure 1 (six-minute walk): week 24 mean change 15.330 m (SD 61.486, n=109) elamipretide and 17.386 m (SD 51.696, n=109) placebo. The registry reports unadjusted means, so it is consistent with the paper but does not reproduce the least-squares difference.","locatorStatus":"partly_matched","limits":["Total fatigue score direction: lower is better on the 4 to 16 scale. The abstract prints the interval as -0.10 to 0.26 around -0.07; WPF reproduces it as printed.","The published figure and table locations in the full text (PMC10382259) were not read in this pass.","The trial was stopped after the double-blind part missed its primary endpoints. A post hoc genotype analysis exists (PMID 39574155) and is not part of this result."],"source":"journey_release","versionedRecordUrl":"https://www.worldpeptidefoundation.org/api/research/journey/elamipretide?version=1.0.0&resultId=mmpower-3-6mwt-24w","citation":"MMPOWER-3 (phase 3, double-blind, placebo-controlled). Elamipretide vs placebo. Primary source: https://doi.org/10.1212/WNL.0000000000207402 (PMID 37268435; NCT03323749). Cited from World Peptide Foundation, Research Journeys, version 1.0.0, result mmpower-3-6mwt-24w. Versioned record: https://www.worldpeptidefoundation.org/api/research/journey/elamipretide?version=1.0.0&resultId=mmpower-3-6mwt-24w. Page: https://www.worldpeptidefoundation.org/research/journey/elamipretide#mmpower-3-6mwt-24w.","verifyUrl":"https://www.worldpeptidefoundation.org/research/journey/elamipretide#mmpower-3-6mwt-24w"},"decisions":[{"id":"fda-forzinity-nda215244","jurisdiction":"United States","regulator":"FDA","product":"FORZINITY (elamipretide) injection, NDA 215244 (Stealth BioTherapeutics)","indication":"Barth syndrome in patients weighing at least 30 kg","actionType":"Accelerated approval (new molecular entity, priority review)","decisionDate":"2025-09-19","dateChecked":"2026-11-13","sourceTitle":"FDA press announcement, 19 September 2025, \"FDA Grants Accelerated Approval to First Treatment for Barth Syndrome\"; openFDA Drugs@FDA record NDA215244 (ORIG-1, status AP, 2025-09-19, priority)","sourceUrl":"https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome","limits":"FDA states the approval rests on improved knee-extensor muscle strength, a measure reasonably likely to predict benefit, and requires a confirmatory randomized trial. It concerns Barth syndrome only. It says nothing about primary mitochondrial myopathy, the condition tested in MMPOWER-3."}],"sha256":"debf9d1a8208905fb8396e3dca83b27c93a7eeb5aceda7004695d5ec8206148d"}